zur Navigation zum Inhalt

Onkologie

Das Lungengewächs danach

© Gernot Seebacher
07/2017 Expertenbericht. Der Lungenkrebs gehört zum Rauchen, wie der klischeehafte Kaffee. Aufgrund der Qualmverliebtheit ist er weiterhin der häufigste Krebs weltweit, doch haben die Ärzte heute ein paar Therapien mehr im Ärmel. [...]

American Society of Hematology 2016 annual meeting

07/2017 Summary

At the last meeting of the American Society of Hematology (ASH), data on first-line treatment with obinutuzumab in indolent lymphoma, as well as promising data on the long-term observation of chronic lymphocytic leukemia (CLL) patients treated with ibrutinib, were presented. [...]

ASH Meeting 2016: developments in hemostaseology

07/2017 Summary

During the annual meeting of the American Society of Hematology (ASH) in San Diego/California, novel developments in the field of hemostaseology were presented. Alternative treatment strategies besides factor replacement were discussed for patients with hemophilia. [...]

Is there progress in the treatment of high-risk myeloma?

07/2017 Summary

Treatment of high-risk patients is a major challenge in multiple myeloma (MM). Median survival rates of these patients remain poor at about 2 years and there were no major improvements with the introduction of immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). [...]

Hematopoietic stem cell transplantation: up-date from ASH 2016

07/2017 Summary

Allogeneic hematopoietic stem cell transplantation (allo HSCT) offers a potentially curative approach for acute myeloid leukemia (AML) with intermediate or adverse risk according to the recently published European Leukemia Network (ELN) guidelines. [...]

Post San Antonio Breast Cancer Symposium

07/2017 The 2016 SABCS (San Antonio Breast Cancer Symposium) provided delegates with a number of interesting and some praxis-changing data. This issue of memo highlights the most relevant data from the SABCS presented by leading breast cancer experts from Austria. [...]

Medizin heute

Aktuelle Printausgaben

SCHWERPUNKTE ONKOLOGIE

I-O P-Z